US Medicare began covering weight-loss GLP-1s at a capped copay, after decades of exclusion
The Medicare GLP-1 Bridge Program launched on 1 July 2026, giving eligible Medicare Part D enrollees access to specified GLP-1 products for obesity at a capped out-of-pocket cost of around 50 dollars a month. Under existing federal law Part D plans cannot cover medicines prescribed for weight loss, so the programme runs as a separate demonstration with a central Medicare system handling approvals and payments. It runs to 31 December 2027, after the Part D portion of a broader model was delayed indefinitely in May 2026.
What this actually means
Nothing here changes UK access. It is worth watching for a different reason: it is the largest test yet of what happens when a national payer opens the taps on these drugs.
The UK is running the same experiment with different mechanics. NHS access through NICE criteria and the GP contract is rationing by eligibility rather than by copay, and both systems are trying to answer the same question: how do you fund an effective drug for a very common condition without the budget collapsing.
The useful detail is the structure. Medicare had to build a separate programme because its own law forbids covering weight-loss drugs, a rule written when weight loss was assumed to be cosmetic. That is a good illustration of how far the medical understanding has moved ahead of the rules built around it, here as much as there.
Told first, next time
This story reached you late. A short email when a licence changes, a safety alert lands, or a trial reports. No selling, no advertising, no sharing your address.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.